Tricida (TCDA) Reports Q4 Loss of $0.66/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results
March 28, 2019 7:00 AM EDTWebcast Today at 8:00 am Eastern Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida,Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three months and full year ended December 31, 2018 and provided an update on key initiatives.
Recent Highlights
Announced today, initial topline data analyses of the TRCA-301E trial, a placebo-controlled, blinded, 40-week extension... More